- Glaukos Corporation (NYSE:GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare & Medicaid Services (CMS) for 2022.
- See the 8K filing on the update.
- After the CMS published the Final Rule, Stephens has upgraded Glaukos to Overweight from Equal Weight, with a price target of $68, up from $60.
- The analyst Chris Cooley noted a favorable reimbursement outlook for devices used for micro-invasive glaucoma surgery (MIGS).
- According to Piper Sandler, Glaukos is a ‘big beneficiary’ of the final CMS ruling.
- Analyst Matt O’Brien tells investors that the Company’s facility cut has been largely reversed and its physician cut reduced.
- Related: William Blair Downgrades Glaukos After Disappointing CMS Rate; Shares Drop.
- Price Action: GKOS shares are up 20.8% at $54.45 during the market session on the last check Wednesday.
Why Are Glaukos Shares Rallying Today?
Glaukos Corporation (NYSE: GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare & Medicaid Services (CMS) for 2022.
